Strict monitoring and surveillance systems for the safety of all vaccines, including those for COVID-19, are in place during vaccine trials as well as once vaccines are rolled out more widely. Adele Baleta takes a look at how vaccine-related adverse events are monitored in South Africa.
Government deserves criticism for various aspects of its COVID-19 response, but some social media criticism following Sunday’s announcement that the Oxford University/AstraZeneca vaccine has little or no efficacy in preventing mild-to-moderate disease caused by the 501Y.V2 variant has been unfair, writes Marcus Low.
In allowing section 21 applications as part of a controlled compassionate access programme, SAHPRA has essentially shifted the responsibility for deciding whether the anti-parasitic ivermectin is safe and effective enough to be used in the treatment of COVID-19 to doctors. This places an enormous responsibility on doctors, writes Adele Baleta.
South Africa has struggled to secure adequate stock of urgently needed COVID-19 vaccines. This has raised questions about the state of the country’s local vaccine manufacturing capacity and why, after almost two decades of government support, South Africa’s partially state-owned vaccine manufacturer Biovac is not better positioned to respond to the pandemic. Catherine Tomlinson investigates.
The delivery of a safe and effective COVID-19 vaccine once it becomes available in South Africa will be a complex and costly logistical exercise. Acquiring enough injection devices is part of crucial logistical planning to ensure rapid, equitable access to COVID-19 vaccines. Adele Baleta reports.
HIV medicines for children often taste bitter, pills are large, and for many children there is a lot of medication to take. This makes it hard to take treatment as prescribed. Tiyese Jeranji looks at the challenges with currently available HIV medicines for children, what innovations are in the pipeline, and how HIV treatment is being tailored to suit the needs of children.
A recent announcement about a vaginal ring to prevent HIV has AIDS activists and women’s sexual and reproductive health advocates excited. But where would this ring fit in South Africa’s HIV prevention programme? Amy Green investigates.
Recently the South African Health Products Regulatory Authority was criticised for not approving laboratory-based SARS-CoV-2 antibody tests. Spotlight Editor Marcus Low argues that despite the regulator’s capacity constraints, its flexible conservatism is something to be grateful for.
The MCC will soon be replaced by the South African Health Products Authority (SAHPRA). Spotlight asked MCC registrar Dr Joey Gouws and MCC chairperson Professor Helen Rees about changes at South Africa’s medicines regulator.